» Articles » PMID: 34073306

Genetic Counselling Improves the Molecular Characterisation of Dementing Disorders

Overview
Journal J Pers Med
Date 2021 Jun 2
PMID 34073306
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Dementing disorders are a complex group of neurodegenerative diseases characterised by different, but often overlapping, pathological pathways. Genetics have been largely associated with the development or the risk to develop dementing diseases. Recent advances in molecular technologies permit analyzing of several genes in a small time, but the interpretation analysis is complicated by several factors: the clinical complexity of neurodegenerative disorders, the frequency of co-morbidities, and the high phenotypic heterogeneity of genetic diseases. Genetic counselling supports the diagnostic path, providing an accurate familial and phenotypic characterisation of patients. In this review, we summarise neurodegenerative dementing disorders and their genetic determinants. Genetic variants and associated phenotypes will be divided into high and low impact, in order to reflect the pathologic continuum between multifactorial and mendelian genetic factors. Moreover, we report a molecular characterisation of genes associated with neurodegenerative disorders with cognitive impairment. In particular, the high frequency of rare coding genetic variants in dementing genes strongly supports the role of geneticists in both, clinical phenotype characterisation and interpretation of genotypic data. The smart application of exome analysis to dementia patients, with a pre-analytical selection on familial, clinical, and instrumental features, improves the diagnostic yield of genetic test, reduces time for diagnosis, and allows a rapid and personalised management of disease.

Citing Articles

A Comprehensive Review of Modifiable Cardiovascular Risk Factors and Genetic Influences in Dementia Prevention.

Khan M, Jaiswal A, Wandile B Cureus. 2023; 15(11):e48430.

PMID: 38074067 PMC: 10702146. DOI: 10.7759/cureus.48430.


Genetic testing-whether to allow complete freedom? Direct to consumer tests versus genetic tests for medical purposes.

Malgorzata M, Maria S, Michal W J Appl Genet. 2021; 63(1):119-126.

PMID: 34826052 PMC: 8755658. DOI: 10.1007/s13353-021-00670-z.

References
1.
Sun J, Tan L, Wang H, Tan M, Tan L, Li J . Genetics of Vascular Dementia: Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015; 46(3):611-29. DOI: 10.3233/JAD-143102. View

2.
Riedijk S, Niermeijer M, Dooijes D, Tibben A . A decade of genetic counseling in frontotemporal dementia affected families: few counseling requests and much familial opposition to testing. J Genet Couns. 2009; 18(4):350-6. PMC: 2706981. DOI: 10.1007/s10897-009-9222-3. View

3.
Goldman J, Rademakers R, Huey E, Boxer A, Mayeux R, Miller B . An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology. 2011; 76(5):475-83. PMC: 3034412. DOI: 10.1212/WNL.0b013e31820a0d13. View

4.
Moore K, Nicholas J, Grossman M, McMillan C, Irwin D, Massimo L . Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2019; 19(2):145-156. PMC: 7007771. DOI: 10.1016/S1474-4422(19)30394-1. View

5.
Goldman J, Van Deerlin V . Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. Mol Diagn Ther. 2018; 22(5):505-513. PMC: 6472481. DOI: 10.1007/s40291-018-0347-7. View